BC024659 Inhibitors
BC024659 inhibitors form a class of chemicals that primarily act by modulating cell cycle progression and transcriptional regulation, targeting key kinases and cyclin-dependent kinases (CDKs). The selected inhibitors, such as BI-2536, Seliciclib, and RO-3306, exert their effects by inhibiting PLK1 and CDKs, disrupting the cell cycle. These inhibitors may impact BC024659, as it could be involved in cell cycle regulation.
Palbociclib, LY2857785, VX-680, AT7519, Dinaciclib, THZ1, AZD5438, TG-02, and SNS-032 target various CDKs involved in cell cycle progression and transcriptional regulation. These inhibitors, by modulating the activity of specific CDKs, can potentially influence BC024659, which may be functionally connected to these cellular processes. The intricate regulation of BC024659 and its potential involvement in the cell cycle and transcriptional control make these inhibitors valuable tools for investigating its functions at the molecular level.
Understanding the class of BC024659 inhibitors involves recognizing their intricate interactions with key regulatory proteins and pathways involved in cell cycle progression and transcriptional regulation. These inhibitors offer a comprehensive approach to studying BC024659 by specifically intervening in the processes associated with its potential functions. The class provides a versatile toolkit for investigating and modulating BC024659 functionality, offering insights into its regulatory mechanisms in cellular processes. The intricate connections between BC024659 and cell cycle progression or transcriptional regulation highlight the significance of these inhibitors in unraveling the roles played by BC024659 in cellular homeostasis and disease-related processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $148.00 $515.00 | 8 | |
BI-2536 inhibits PLK1, a kinase involved in cell cycle regulation. Its action disrupts cell cycle progression, potentially impacting BC024659, which may have cell cycle-related functions. | ||||||
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $65.00 $160.00 $320.00 | 37 | |
RO-3306 is a selective CDK1 inhibitor, impacting cell cycle progression. Its action can potentially influence BC024659, which may have functions related to the cell cycle. | ||||||
PD 0332991 Isethionate | 827022-33-3 | sc-478943 | 1 mg | $300.00 | ||
Palbociclib inhibits CDK4 and CDK6, disrupting cell cycle progression. Its action may impact BC024659, which could be associated with cell cycle regulation. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $61.00 $85.00 | 4 | |
VX-680 inhibits multiple kinases, including PLK1. Its action disrupts cell cycle progression, potentially impacting BC024659, which may be involved in cell cycle regulation. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $207.00 $246.00 $1025.00 $3065.00 | 1 | |
AT7519 inhibits multiple CDKs, affecting cell cycle progression. Its action may impact BC024659, which could be associated with functions related to the cell cycle. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib inhibits CDK1, CDK2, CDK5, and CDK9, impacting cell cycle progression and transcriptional regulation. Its action can potentially influence BC024659, involved in these processes. | ||||||
THZ1 | 1604810-83-4 | sc-507542 | 1 mg | $95.00 | ||
THZ1 inhibits CDK7, affecting transcriptional regulation. Its action may impact BC024659, which could be associated with functions related to transcriptional control. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9, affecting cell cycle progression and transcription. Its action can potentially influence BC024659, which may be involved in these processes. | ||||||
Zotiraciclib | 937270-47-8 | sc-507450 | 10 mg | $202.00 | ||
This compound, also called TG-02, inhibits CDKs and FLT3, affecting cell cycle progression and signaling. Its action may impact BC024659, which could be associated with functions related to the cell cycle and signaling. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 inhibits CDK2, CDK7, and CDK9, affecting cell cycle progression and transcription. Its action can potentially influence BC024659, involved in these processes. | ||||||